Search
BHT-3034
go.drugbank.com/drugs/DB18045ExperimentalBHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]
Lisaftoclax
go.drugbank.com/drugs/DB18054InvestigationalLisaftoclax is a novel, orally active, selective and potent BCL-2 inhibitor
PLG-0206
go.drugbank.com/drugs/DB18116InvestigationalPLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.[L48106]
OTOF-GT
go.drugbank.com/drugs/DB18129InvestigationalOTOF-GT is a dual vector AAV gene therapy being investigated for the restoration of hearing loss associated with otoferlin deficiency.
PBKR03
go.drugbank.com/drugs/DB18138InvestigationalPBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
TN-401
go.drugbank.com/drugs/DB18140InvestigationalTN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Synonyms: A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 geneEfocipegtrutide
go.drugbank.com/drugs/DB18194InvestigationalEfocipegtrutide is a long-acting, monomeric peptide triple agonist.
Synonyms: IMMUNOGLOBULIN G4 (HUMAN .GAMMA.4-CHAIN C REGION C-TERMINAL FRAGMENT), DIMER, 1-(1-(3-HYDROXYPROPYL)-L-PROLINE), 1-ETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYLXMT-2056
go.drugbank.com/drugs/DB18230InvestigationalXMT-2056 is a HER2-targeted antibody-drug conjugate (ADC) consisting of a HER2-targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload.
AP103
go.drugbank.com/drugs/DB18234ExperimentalAP103 is a non-viral gene therapy that uses a delivery vector, HPAE (Highly Branched Poly β-Amino Ester), to deliver the correct collagen VII gene into skin cells.
Nerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigational[L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade. … Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer.